Quadrant Management

Vantem Global specializes in the manufacturing of a proprietary panel sheet system designed for construction applications. The company focuses on producing structural insulated panels that facilitate the construction of volumetric modules in a factory setting, which are then transported to the building site for final assembly. Vantem's panels are weather-resistant, thermally efficient, and finish-ready, making them suitable for constructing a variety of buildings, including homes. By streamlining the construction process, Vantem enables builders to reduce costs and shorten delivery times, ultimately enhancing profitability through increased efficiency. The company's approach supports the rapid delivery of energy-efficient and climate-resistant homes, contributing to the overall modernization of the construction industry.

Vantem Global specializes in the manufacturing of a proprietary panel sheet system designed for construction applications. The company focuses on producing structural insulated panels that facilitate the construction of volumetric modules in a factory setting, which are then transported to the building site for final assembly. Vantem's panels are weather-resistant, thermally efficient, and finish-ready, making them suitable for constructing a variety of buildings, including homes. By streamlining the construction process, Vantem enables builders to reduce costs and shorten delivery times, ultimately enhancing profitability through increased efficiency. The company's approach supports the rapid delivery of energy-efficient and climate-resistant homes, contributing to the overall modernization of the construction industry.

Wandercraft SAS, founded in 2012 and based in Paris, France, specializes in the development of exoskeleton technology aimed at patients with mobility limitations due to spinal cord injuries, neuromuscular diseases, and strokes. The company's flagship product, Atalante, is a self-balancing, hands-free exoskeleton designed for rehabilitation in health centers, allowing users to walk without the need for crutches or additional technical aids. CE-marked in 2019, Atalante is sold to European rehabilitation hospitals to enhance gait re-learning treatments. Additionally, Wandercraft is working on a more compact exoskeleton for personal mobility in everyday life. The company integrates expertise in areas such as robotics, artificial intelligence, and clinical applications, making it a pioneer in creating realistic, autonomous walking devices for individuals with walking impairments.

SyncThink Inc. is a neuro-technology company based in Palo Alto, California, specializing in eye-tracking technology for brain health assessment. Founded in 2009 by Dr. Jamshid Ghajar, the company has developed the EYE-SYNC device, a rapid, non-invasive tool designed to evaluate ocular motor impairments and vestibular dysfunction, key indicators of concussion. The EYE-SYNC assessment takes just 60 seconds and is used by various institutions, including university athletic departments and medical clinics like Stanford University and Massachusetts General Hospital. SyncThink has established partnerships with prominent research organizations, securing over $36 million in funding from the US Department of Defense for its development and research initiatives. The technology is FDA approved and supported by a robust intellectual property portfolio, including eleven issued patents. SyncThink's offerings extend beyond concussions, with potential applications in attention development, brain performance enhancement, and fatigue evaluation.

SyncThink Inc. is a neuro-technology company based in Palo Alto, California, specializing in eye-tracking technology for brain health assessment. Founded in 2009 by Dr. Jamshid Ghajar, the company has developed the EYE-SYNC device, a rapid, non-invasive tool designed to evaluate ocular motor impairments and vestibular dysfunction, key indicators of concussion. The EYE-SYNC assessment takes just 60 seconds and is used by various institutions, including university athletic departments and medical clinics like Stanford University and Massachusetts General Hospital. SyncThink has established partnerships with prominent research organizations, securing over $36 million in funding from the US Department of Defense for its development and research initiatives. The technology is FDA approved and supported by a robust intellectual property portfolio, including eleven issued patents. SyncThink's offerings extend beyond concussions, with potential applications in attention development, brain performance enhancement, and fatigue evaluation.